Cite
Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT.
MLA
Ramalingam, Sendhilnathan, et al. “Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT.” Biology of Blood & Marrow Transplantation, vol. 26, Mar. 2020, pp. S48–49. EBSCOhost, https://doi.org/10.1016/j.bbmt.2019.12.120.
APA
Ramalingam, S., Siamakpour-Reihani, S., Bohannon, L., Ren, Y., Sibley, A., Nixon, A., Lyu, J., Xie, J., Choi, T., Gasparetto, C., Horwitz, M. E., Long, G. D., Lopez, R., Rizzieri, D. A., Sarantopoulos, S., Chao, N. J., & Sung, A. D. (2020). Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT. Biology of Blood & Marrow Transplantation, 26, S48–S49. https://doi.org/10.1016/j.bbmt.2019.12.120
Chicago
Ramalingam, Sendhilnathan, Sharareh Siamakpour-Reihani, Lauren Bohannon, Yi Ren, Alexander Sibley, Andrew Nixon, Jing Lyu, et al. 2020. “Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT.” Biology of Blood & Marrow Transplantation 26 (March): S48–49. doi:10.1016/j.bbmt.2019.12.120.